Relevance of TNBS-Colitis in Rats: A Methodological Study with Endoscopic, Historical and Transcripttomic Characterization and Correlation to IBD by Brenna, Øystein et al.
Relevance of TNBS-Colitis in Rats: A Methodological
Study with Endoscopic, Histologic and Transcriptomic
Characterization and Correlation to IBD
Øystein Brenna1,2*, Marianne W. Furnes2, Ignat Drozdov3, Atle van Beelen Granlund2, Arnar Flatberg2,
Arne K. Sandvik1,2, Rosalie T. M. Zwiggelaar2, Ronald Ma˚rvik2,4, Ivar S. Nordrum2,5, Mark Kidd6,
Bjo¨rn I. Gustafsson1,2
1Department of Gastroenterology and Hepatology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 2Department of Cancer Research and Molecular
Medicine, Norwegian University of Science and Technology, Trondheim, Norway, 3 Bering Limited, Richmond, United Kingdom, 4Department of Gastrointestinal Surgery, St.
Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, 5Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital,
Trondheim, Norway, 6Department of Surgery, Section of Gastroenterology, Yale School of Medicine, New Haven, Connecticut, United States of America
Abstract
Background: Rectal instillation of trinitrobenzene sulphonic acid (TNBS) in ethanol is an established model for inflammatory
bowel disease (IBD). We aimed to 1) set up a TNBS-colitis protocol resulting in an endoscopic and histologic picture
resembling IBD, 2) study the correlation between endoscopic, histologic and gene expression alterations at different time
points after colitis induction, and 3) compare rat and human IBD mucosal transcriptomic data to evaluate whether TNBS-
colitis is an appropriate model of IBD.
Methodology/Principal Findings: Five female Sprague Daley rats received TNBS diluted in 50% ethanol (18 mg/0.6 ml)
rectally. The rats underwent colonoscopy with biopsy at different time points. RNA was extracted from rat biopsies and
microarray was performed. PCR and in situ hybridization (ISH) were done for validation of microarray results. Rat microarray
profiles were compared to human IBD expression profiles (25 ulcerative colitis Endoscopic score demonstrated mild to
moderate colitis after three and seven days, but declined after twelve days. Histologic changes corresponded with the
endoscopic appearance. Over-represented Gene Ontology Biological Processes included: Cell Adhesion, Immune Response,
Lipid Metabolic Process, and Tissue Regeneration. IL-1a, IL-1b, TLR2, TLR4, PRNP were all significantly up-regulated, while
PPARc was significantly down-regulated. Among genes with highest fold change (FC) were SPINK4, LBP, ADA, RETNLB and
IL-1a. The highest concordance in differential expression between TNBS and IBD transcriptomes was three days after colitis
induction. ISH and PCR results corresponded with the microarray data. The most concordantly expressed biologically
relevant pathways included TNF signaling, Cell junction organization, and Interleukin-1 processing.
Conclusions/Significance: Endoscopy with biopsies in TNBS-colitis is useful to follow temporal changes of inflammation
visually and histologically, and to acquire tissue for gene expression analyses. TNBS-colitis is an appropriate model to study
specific biological processes in IBD.
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Introduction
Inflammatory bowel disease (IBD) is the common denomination
of ulcerative colitis (UC) and Crohn’s disease (CD). The etiology is
unknown and the pathogenesis is complex and incompletely
understood. The interplay between genetic and immunological
host factors and the gut microbiota are important factors in the
development of disease [1,2].
The inflammatory response in IBD is characterized by mucosal
barrier dysfunction, microbial invasion and activation of immune
response [3,4]. In genetically predisposed individuals, microbial
activation via toll-like receptors (TLRs) and induction of an
inflammatory response accompanied by high levels of pro-
inflammatory cytokines such as interleukins (ILs) (IL-1, IL-6, IL-
13 and IL-17) and tumor necrosis factor alpha (TNF-a), seem to
be critical [1,5–9]. However, the exact molecular basis of IBD
remains poorly understood.
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Experimentally induced colitis with trinitrobenzene sulphonic
acid (TNBS) is used to generate models that are used to examine
the pathogenesis of gut inflammation, and determine the
mechanisms and efficacy of therapies [10]. TNBS is diluted in
ethanol which disrupts the mucosal barrier. Usually, the TNBS-
solution is rectally instilled. Inflammation is induced by TNBS-
induced haptenization of colonic mucosal proteins [11]. The use of
TNBS to generate colitis was originally described and histologi-
cally characterized by Morris et al. in rats. Granulomas were
observed in over 50% of animals two to three weeks after
induction of colitis [12]. TNBS-ethanol administration is charac-
terized by Th1-driven inflammation [11], and has primarily been
regarded as a model for CD [10,13]. The clinical features include
weight loss and bloody diarrhea, while morphologically the model
is characterized by mucosal, submucosal and transmural inflam-
mation. Consequently, the model has been used to investigate the
role and mechanistic action of drugs including 5-aminosalisylic
acid, steroids and anti-tumor necrosis factor (TNF) in IBD [14–
16]. The administration and doses of TNBS differ significantly
between studies; the methodology is inconsistent and no
standardized protocol exists [14,17–20].
Both TNBS-colitis and IBD include disturbances in basic
physiological processes like immune activation, metabolism and
mucosal repair [21]. Microbial regulation of TLRs and induction
of an inflammatory response is accompanied by regulation of pro-
and anti-inflammatory cytokines and the shaping of the intestinal
immune response [22]. Down-regulation of the peroxisome
proliferator-activated receptor (PPAR) gamma involved in the
regulation of fatty acid metabolism and inflammation, has been
demonstrated in IBD and is associated with maintenance of
defensin expression [23–25]. The cellular Prion protein (PrPc) is
expressed in brain and various extra cerebral tissues including
neuroendocrine cells and lymphoid tissue of the gut [26–28]. PrPc
can have an anti-inflammatory effect in the colon [29].
We report the development and characterization of TNBS-
colitis in rats using colonoscopy and temporal gene expression
profiling. The aim was to standardize TNBS administration to
achieve a moderate inflammation. Achieving a moderate colitis
allowed for the study of epithelial alterations upon mucosal
damage, while temporal gene expression profiling identified
longitudinal transcriptomic changes that were associated with
these abnormalities. We further aimed to compare the genome-
wide changes in TNBS-colitis to a human transcriptome to
determine whether TNBS at this dose was an appropriate model
for IBD.
Materials and Methods
Animals
The study was approved by the National Animal Research
Authority (NARA). The general care and use of the animals were
in accordance with the European Convention for the protection of
Vertebrate Animals used for Experimental and other Scientific
purposes. We used female Sprague Dawley rats weighing 200–
250 g from Taconic (Taconic Farms, Inc., Hallingore, Denmark).
They were housed in individually ventilated cages (IVC) with
aspen bedding (Tapvei) in a specific pathogen free (SPF)
environment with temperature 19–22uC and humidity 50–60%
and 12 hr day and night cycle with 1 hr dusk and dawn. All rats
had access to water and standard chow (RM1 maintenance, SDS,
UK) ad libitum, apart from the 24 hr fasting periods before each
colonoscopy to allow voiding of the left colon, when they had
access only to glucose 2% fluid mixture and were kept in wired
bottom cages. Rat colonoscopy was performed under general gas
anesthesia using isoflurane. At termination, the rats were sacrificed
by exsanguination during general isoflurane anesthesia.
Initial studies and main study
Initial studies to optimize TNBS dose and
concentration. Sixteen rats weighing 264.9 g (standard devia-
tion [SD] 614.5) were divided into two groups. Group 1 received
17.5 and group 2 received 22.5 mg TNBS (1 M, 293.17 mg/ml,
product number 92822, Fluka, Buchs, Switzerland) diluted in 50%
ethanol to a concentration of 60 mg/ml. The total volume instilled
was ,0.29 ml and ,0.38 ml respectively for group 1 and 2. In a
subsequent study, eight rats received TNBS in eight different doses
(7–31.5 mg) diluted in 50% ethanol, to a total volume of 0.7 ml
with concentrations ranging from 10–45 mg/ml.
TNBS was rectally instilled via a female urinary catheter (DCT
Ch 10, Servoprax GmbH, Wesel, Germany). After removal of
residual rectal fecal pellets, the catheter was advanced approx-
imately to the splenic flexure. After instillation, the rats were held
with the head down for one minute to prevent TNBS from leaking
out. The colitis was evaluated with colonoscopy (Olympus uretero-
renoscope, URF Type V) with picture documentation at Day 3,
Day 7 and at Day 12. Biopsies were obtained using an Olympus
biopsy forceps (FB-56 D-1, Olympus, Norway).
Main study. Eight female Sprague Dawley rats, age eight
weeks and weighing 196.9 g (SD614.3) were used. Based on the
initial studies, TNBS dissolved in 50% ethanol to a concentration
of 30 mg/ml in a total volume of 0.6 ml was instilled. Animal
Figure 1. Endoscopic images demonstrating the effect of
different doses of TNBS in a fixed concentration of 60 mg/ml.
Severe colitis with a yellowish membrane and coprostasis was noted at
day 3, and mucosal shedding, stenosis and necrosis was evident at day
7 in rats given TNBS 17.5 mg and 22.5 mg (0.29 ml and 0.38 ml,
respectively). The bottom panel depicts examples of normal rat colon.
doi:10.1371/journal.pone.0054543.g001
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weights and clinical status were monitored throughout the study.
Colonoscopy with photo documentation and tissue sampling was
performed two days before (T0), and three (T3), seven (T7) and
twelve (T12) days after induction of colitis. A modified Murine
Endoscopic Index of Colitis Severity [30] (MEICS, 0–12,
Thickening of the colon was not considered) was used for endoscopic
evaluation and grading of the colitis. Five animals that developed
similar endoscopically moderate colitis in the left colon were
chosen for further studies.
During each colonoscopy, three biopsies were collected and
snap frozen in liquid nitrogen for later RNA extraction. Another
two biopsies were fixed in 4% buffered formaldehyde and then
embedded in paraffin. The study was terminated at T12. The
colon was divided longitudinally and one part fixed in formalde-
hyde for histologic examination and the other frozen in liquid
nitrogen.
Animal weight data were compared using Student’s t-test with
equal variances after confirming this with f-test. The significance
level was set at a=0.05.
RNA extraction, microarray amplification, hybridization,
scanning and quantification
Rat mucosal samples. From each animal, three biopsies
were collected at every time point in the main study (TNBS
30 mg/ml, 0.6 ml). Samples were pooled and RNA was extracted
using the RNeasy Mini RNA extraction Kit (cat.no. 74106,
Qiagen, Hilden, Germany) according to the manufacturer’s
protocol. Quality of extracted RNA was controlled using
Figure 2. Endoscopic images demonstrating the effect of TNBS at different concentrations instilled rectally in a total volume of
0.7 ml. TNBS 10.5 mg (15 mg/ml) was associated with minimal mucosal inflammation and edema. TNBS 21.0 mg (30 mg/ml) resulted in an
erythematous and edematous mucosa at day 3 and 7. At day 12 mucosal granulation and ulcerations were seen. TNBS 24.5 mg (35 mg/ml) and
31.5 mg (45 mg/ml) resulted in a more severe acute inflammation, and at day 7, larger areas of ulceration with fibrin cover were visible. At day 12,
stenotic strictures developed in the rat receiving TNBS 24.5 mg. The rat receiving 31.5 mg was euthanized after the second endoscopy and
consequently no endoscopic picture from day 12 can be shown. In the right column, histological pictures corresponding to mild, moderate and
severe TNBS-colitis are included. TNBS 10.5 mg (15 mg/ml) resulted in only minimal inflammation with some architectural changes. TNBS 21.0 mg
(30 mg/ml) resulted in ulceration that bordered the mucosa with inflammatory cell infiltration. In TNBS 24.5 mg (35 mg/ml), crypt distortion and
abscesses (arrows) with mucosal and submucosal inflammatory infiltration were visible. Severe TNBS colitis is seen in the lower hitstologic picture
with transmural inflammatory cell infiltration and total denudation of the mucosa. Objective x10 in all histological images.
doi:10.1371/journal.pone.0054543.g002
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NanoDrop Spectrophotometer (Thermo Scientific, DE, USA) and
Bioanalyzer (Agilent Technologies, CA, USA). Samples with
RIN.7 were deemed suitable for downstream analysis. Biotiny-
lated cRNA was prepared from 400 ng RNA for each sample
using the Illumina TotalPrep RNA Amplification kit (Applied
Biosystems/Ambion, Austin, TX, USA). Sample cRNA was
subsequently hybridized on Illumina human RatRef-12 v1
expression BeadChips (Illumina, San Diego, CA, USA) and
scanned on an Illumina BeadStation. Data from this analysis is
publicly available at ArrayExpress, E-MTAB-1263.
Human mucosal samples. Gene expression profiles in
mucosal samples from 25 patients with UC, 11 patients with
CD, and 25 healthy controls were used for comparison with the
TNBS-transcriptomes. The data used was drawn from a larger
IBD gene expression analysis study performed at Norwegian
University of Science and Technology/St. Olavs Hospital,
Trondheim, Norway. All IBD samples were obtained from
maximally inflamed colonic mucosa, while normal controls were
taken from the hepatic flexure. Four endoscopic pinch biopsies
were collected from each area. Three biopsies were immediately
snap frozen in liquid nitrogen, while the remaining sample was
fixed in 4% buffered formaldehyde. The formaldehyde-fixed
samples were embedded in paraffin and 4 mm sections were cut
and stained with hematoxylin-eosin for histological evaluation by
an experienced pathologist. In cases where the evaluation differed
from the macroscopic observations, samples were removed from
the analysis. Frozen biopsies were homogenized using an Ultra-
Turrax T 25 homogenizer (Zanke & Kunkel IKA-Laboratorie
Technik, Staufen, Germany). Total RNA was extracted using
Ambion mirVanaTM miRNA Isolation Kit (Applied Biosystems,
Foster City, CA, USA). RNA quantity, purity and integrity were
assessed using a NanoDropTM Spectrophotometer (Thermo
Scientific, Wilmington, DE, USA) and Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). Only samples with a
RIN.7 were used in the subsequent microarray analysis. For each
sample, 250 ng total RNA was used to generate biotinylated,
amplified cRNA following the Illumina TotalPrer RNA Amplifi-
cation Kit (Applied Biosystems/Ambion, Austin, TX, USA). The
samples were hybridized on Illumina HT12 expression BeadChips
(Illumina, San Diego, CA, USA) and scanned on an Illumina
BeadStation. Informed written consent was obtained from all
involved patients, and the study was approved by the Regional
Medical Research Ethics Committee (approval no 5.2007.910).
The study was registered in the Clinical Trials Protocol
Registration System (identifier NCT00516776). Data from this
analysis is publicly available at ArrayExpress, E-MTAB-184.
Data preparation and bioinformatic analysis
Gene expression analysis. Raw data was exported from the
Illumina GenomeStudio software and normalized using the lumi
package for Bioconductor suite [31]. The data was quantile
normalized and log2 transformed. Time course differential gene
expression analysis was performed using the BETR package for R
statistical environment [32]. Pairwise group comparisons were
performed using a Student’s t-test. The (FC) was used to express
the changes in average gene expressions between studied groups.
To standardize annotation across microarray platforms, Illumina
probe identifiers were mapped to their corresponding Ensembl
(accessed March 23, 2011) gene identifiers (IDs) [33].
Clusters of similar gene expression profiles were identified using
the Affinity propagation (AP) algorithm [34], where dissimilarity
was expressed as the negative Euclidian distance. Subsequently,
gene clusters were enriched for over-represented Gene Ontology
(GO) Biological Process (BP) terms [35] using the hypergeometric
test. For a cluster with n genes and an a priori defined functional
category with K genes, the hypergeometric test was used to
evaluate the significance of overlap k between the cluster and GO-
BP category [36,37]. All N genes on a microarray were used as
reference. To ensure specificity of annotation within a gene
cluster, functional categories containing ,5 or .1000 genes were
removed.
Figure 3. Representative endoscopic images of TNBS (30 mg/ml, 0.6 ml) associated changes at different time points and MEICS-
score at T0, T3, T7 and T12. (A) Granulated and edematous mucosa at T3 and T7, and ulcerations at T12 were evident in Rat 1. At T7, small
ulcerations/erosions were identified in Rat 4. In Rat 5, an ulceration is visible at T7 and at T12, a stricturing ulcer has developed. (B) The MEICS-score at
T3 was significantly different from T12 (p= 0.02).
doi:10.1371/journal.pone.0054543.g003
Figure 4. Histologic appearance of an endoscopic biopsy and
whole colon specimen. (A) Endoscopic biopsy collected at T7
showing evidence of a crypt abscess (arrow), and mucosal gland
distortion. Objective x40. (B) Histologic image of a whole colon
specimen collected at termination of the study (T12) identifying
distorted mucosal glands, and an ulceration with completed reepithe-
lialization and underlying submucosal inflammation (arrow). Objective
x4. The slides were stained with hematoxylin and eosin.
doi:10.1371/journal.pone.0054543.g004
Correlation between TNBS-Colitis and IBD
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Comparison of TNBS to IBD transcriptomes
Concordance between TNBS-colitis and IBD transcriptomes
was assessed at the level of individual gene loci as well as at the
level of KEGG [38] and Reactome pathways [39]. To standardize
comparisons between rat and human data, rat gene Ensembl IDs
were mapped to respective human orthologs. In total, 6142 genes
were considered. TNBS-colitis FCs were calculated by comparing
gene expression profiles at T3, T7, and T12 to T0. Similarly, IBD
FCs were computed by comparing CD and UC samples to normal
(N) tissue. At the level of single gene loci, concordance tests were
carried out by correlating FCs of the TNBS-colitis and IBD
transcriptomes. Gene expression profiles with Student’s t-test
p,0.05 and absolute log2 FC $1.1 were considered differentially
regulated.
To assess concordance at the level of biological pathways, gene
expression FCs in TNBS-colitis and IBD transcriptomes were
mapped to respective Reactome and KEGG pathways. To ensure
that only well-characterized cascades were studied, pathways with
fewer than 5 genes were excluded. Subsequently, a pathway-level
FC was computed by averaging FCs of all genes that mapped to a
specific pathway. Finally, TNBS-colitis and IBD pathway level
FCs were correlated.
For all comparisons, Spearman’s rho was used to estimate
correlations between TNBS-colitis and IBD FCs. Respective p-
values were computed for testing the hypothesis of no correlation
against the alternative that there is a nonzero correlation and
p,0.05 was called statistically significant. Analysis was performed
using the Statistics toolbox for Matlab (2009a, The MathWorks,
Natick, MA, USA).
Candidate genes
Interleukin 1 alpha (IL-1a) and interleukin 1 beta (IL-1b) were
chosen as general markers of inflammation. TLR2 and TLR4
were considered markers of bacterial regulation of inflammatory
responses. In addition, based on the degree of regulation and
statistical significance, genes encoding the peroxisome proliferator-
activated receptor gamma (PPARc) and the endogenous prion
protein (PRNP [PrPc]) were further evaluated.
Figure 5. Differential expression analysis of the TNBS transcriptome. (A) Scatter plot of the Principal Component Analysis of 8316 genes in
response to TNBS. (B) Expression profiles of genes assigned to the 13 clusters of similar expression (see Table S1). Only differentially expressed genes
are included. (C) Heat map visualizing functional enrichment of the 13 clusters for over-represented Gene Ontology Biological Process terms. Darker
shades represent a greater degree of enrichment.
doi:10.1371/journal.pone.0054543.g005
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Histological evaluation
Endoscopic biopsies and whole colon specimens were fixed in
4% buffered formaldehyde, placed in standard plastic briquettes
for tissue specimens and processed via standard protocols
(dehydration, clearing and paraffinization overnight). Sections
from each block were cut in 4 mm thickness and stained with
hematoxylin-eosin. The slides were examined by a surgical
pathologist (ISN) and the degree and type of inflammation,
ulceration and degree of regeneration/architectural distortion was
assessed.
In situ hybridization
In situ hybridization (ISH) on endoscopic biopsies was
performed using RNA-probes for the following genes: IL-1a
(NM_017019), IL-1b (NM_031512), TLR2 (NM_198769), TLR4
(NM_019178), PPARc (NM_001145367) and PRNP
(NM_012631) with the RNAscopeH 2.0 assay kit (Advanced Cell
Diagnostics Inc., Hayward CA, USA.), according to the manu-
facturer’s protocol. Briefly, endoscopic biopsies were fixed in 4%
buffered formaldehyde for five days and embedded in paraffin.
Sections from each block were cut in 4 mm thickness and baked
1 hr at 60uC prior to use. After de-paraffinization and dehydra-
tion, the biopsies were air dried and treated with peroxidase
blocker before gentle boiling in a pretreat solution for 15 min.
Then, protease was applied for 30 min at 40uC. After pretreat-
ment steps, the target probe was applied and hybridized for 2 hr at
40uC. Thereafter, the amplification steps including application of a
horseradish peroxidase (HRP)-linked labeling probe were per-
formed prior to DAB-visualization.
PCR
RNA from 18 biopsies (no residual RNA was available from rat
2 and 4 at T3 and T7, respectively), was converted to cDNA with
High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s manual. PCR
was performed using TaqManH Array Plates (Life Technolo-
giesTM, Carlsbad, CA, USA) on a Step One PlusTM Real Time
PCR System. Genes with the largest FC alteration in the
microarray data, serine peptidase inhibitor of the Kazal type 4
(SPINK4), adenosine deaminase (ADA), and fatty acid binding
protein (FABP) 1 were analyzed. Actin beta (ACTB) was used as
housekeeping gene. For each time point relative differential
expression was calculated using the ddCT method followed by
two-tailed paired t-test, T0 served as control.
Results
Optimization of the TNBS protocol
In order to standardize the TNBS-protocol to achieve a
moderate colitis, we initially instilled TNBS in two doses (17.5
and 22.5 mg) at a fixed concentration of 60 mg/ml. The
inflammation was severe in seven out of 16 rats in both treatment
groups. MEICS-score ranged from 8–11 (9.960.9) at T7
(Figure 1). The study had to be terminated prematurely for
animal welfare reasons.
The protocol was adjusted and TNBS was administered in
different concentrations and a fixed volume of 0.7 ml. TNBS
concentrations of 10 mg/ml and 15 mg/ml resulted in only slight
endoscopic and histologic inflammation. Mucosal erythema and
edema and histologic submucosal inflammation without ulcera-
tions were seen at a TNBS concentration of 20 mg/ml. TNBS at
25–40 mg/ml resulted in mucosal edema and friability. Histologic
examination revealed ulcerations and submucosal inflammation.
TNBS 30 mg/ml induced a moderate inflammation with MEICS-
score 7 and 5 at day 3 and day 7, respectively. The highest TNBS
concentration (45 mg/ml) induced severe colitis with general
weakening and the rat was therefore euthanized at day 7 (Figure 2).
The protocol optimization demonstrated that 0.7 ml of TNBS
(30 mg/ml) induced a moderate colitis that lasted at least 12 days
and declined between T7 and T12. However, a small fraction of
TNBS tended to leak from the rectum immediately after
instillation. The total volume was therefore reduced to 0.6 ml
for the subsequent study.
Characterization of moderate TNBS-colitis
Five animals treated with TNBS 30 mg/ml (0.6 ml) developed
moderate colitis from the splenic flexure down to the recto-sigmoid
junction. The MEICS-score peaked at T3 (5.660.9, T3 vs. T12,
p=0.02) and T7 (5.061.2, T7 vs. T12, p=0.11) (Figure 3A and
B). An acute weight loss occurred at T3 (196.7614.3 g at T0
versus 187.6617.3 g at T3, mean weight loss 9.3 g, 4.7%,
p=0.003). The animal weights recovered to 200.4624.7 g and
209.4619.2 g at T7 and T12, respectively. Loose and bloody
stools were noticed in two rats. Signs of cryptitis and architectural
Figure 6. Concordance analysis between TNBS-colitis and IBD
transcriptomes at the level of single gene loci. T3 vs. T0, T7 vs. T0
and T12 vs. T0 compared to CD vs. normal (top) and UC vs. normal
(bottom). (A–F) Scatterplots of FCs in rat data (x-axis) compared to FCs
in the human data (y-axis). Rho values correspond to Spearman
correlation coefficients with p-values representing the level of
significance of the correlation. Concordant up- and down-regulated
genes are represented as red and blue circles respectively. Non-
concordant genes are shown as grey circles. Numbers in the legend
correspond to the total number of genes assigned to each category. B,
C, E and F are only shown in the supplemental section (Figure S1).
doi:10.1371/journal.pone.0054543.g006
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distortion were seen in endoscopic biopsies, whereas histologic
examination of whole colon specimens at T12 demonstrated
regenerative changes, ulcerations and transmural inflammation
(Figure 4A and B).
Temporal TNBS-colitis gene expression analysis
Gene expression profiling of biopsies collected at time-points
T0, T3, T7 and T12 was undertaken. After microarray
preprocessing, expression profiles of 8316 genes were reduced to
two Principal Components (PCs) to visualize differences in gene
expression due to TNBS-induced inflammation (Figure 5A).
Colitis induction resulted in distinct gene expression profiles while
inter-individual temporal changes due to TNBS were not obvious.
To identify genes with sustained differential expression across all
time points, the BETR algorithm was used. Genes with differential
expression probabilities .0.99 were called significant. This
analysis returned 3414 significantly regulated genes, which were
subsequently clustered using the AP algorithm (Figure 5B).
Significantly regulated genes were allocated to 13 clusters, with
588 and 63 genes assigned to the largest and smallest clusters,
respectively. The full list of gene cluster assignments can be
accessed in supplementary Table S1. Functional cluster enrich-
ment for over-represented GO-BP terms identified processes such
as Oxidation reduction (Clusters 1 and 3), Cell cycle (Cluster 2) and Cell
adhesion (Cluster 4) (Figure 5C).
Comparison of the TNBS and IBD transcriptomes
To quantitate the similarity between the TNBS and IBD
transcriptomes, differentially expressed genes at T3, T7 and T12
were compared to differentially expressed genes in CD and UC.
Overall, 6142 rat genes could be mapped to human orthologs.
The highest concordance was observed between CD and T3
(rho= 0.26, p = 0; n=300 significantly regulated concordant
genes) (Figure 6A). Similarly, the most concordance in differential
expression was found between UC and T3 (rho= 0.30, p= 0;
n=765 significantly regulated concordant genes) (Figure 6D).
Up-regulated genes in both TNBS-colitis and human IBD
included ADA, PrPc, and IL-1a, while down-regulated genes
consisted of aldehyde dehydrogenase 1 family, member A1
(ALDH1A1), and PPARc. A full list of comparable gene changes
in TNBS–colitis compared to CD and UC is available as
supplementary Table S2.
As disruption in single gene expression can affect behavior of
molecular pathways [40], concordance between the TNBS model
and IBD was also assessed at the level of biological pathways. To
ensure that results reflected a real phenomenon rather than a
database-specific result, the FCs in gene expression were mapped
to their respective identifiers in the KEGG (n=195 pathways) and
Reactome (n=915 pathways) pathway databases. The highest
concordance between CD and TNBS-colitis was observed at T3
(KEGG: Rho=0.47, p= 3610212, Reactome: Rho= 0.39, p = 0)
(Figure 7). Concordant pathways included Reactome pathways
Figure 7. Concordance analysis between TNBS-colitis and IBD transcriptomes at the level of biological pathways. T3 vs. T0 compared
to CD vs. normal (top) and UC vs. normal (bottom). Left, scatter plots of pathway activity scores of KEGG pathways in TNBS and IBD samples. Right,
scatter plots of pathway activity scores of Reactome pathways in TNBS and IBD samples. Rho values correspond to Spearman correlation coefficients
with p-values representing the level of significance of the correlation. Numbers in the legend correspond to the total number of pathways assigned
to each category. A similar figure (Figure S2) for concordant analysis of T7 vs. T0 and T12 vs. T0, compared to CD vs. normal and UC vs. normal is shown
in the supplementary section (KEGG and Reactome score change at the top and bottom, for T7 vs. T0 and T12 vs. T0, respectively).
doi:10.1371/journal.pone.0054543.g007
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such as Apoptosis, Cell junction organization, Interleukin-1 processing; non-
concordant pathways included GABA-A receptor activation, Extrinsic
pathways for apoptosis and Recycling of bile acids and salts. Similarly, the
most concordance was noted between UC and T3 (KEGG:
rho= 0.52, p= 6610215, Reactome: rho= 0.45, p= 0) (Figure 7).
For example, concordant Reactome pathways included Nuclear
receptor transcription pathway, TNF signaling, and VEGF ligand-receptor
interactions, while non-concordant Reactome pathways included
Apoptotic execution phase and TRAIL signaling. The full list of regulated
pathways in TNBS and IBD is accessible through supplementary
Table S3.
In situ hybridization (ISH) of target genes in TNBS-colitis
Markers of mucosal inflammation and selected microarray
targets were analyzed using ISH. These included inflammatory
cytokines (IL-1a and IL-1b) and TLRs (TLR2 and TLR4), as well
as the computationally identified genes PPARc and PRNP.
An overall increase in gene expression of IL-1a and IL-1b was
evident in submucosal inflammatory infiltrates at T3-T12.
However, changes in expression varied with the degree of
inflammation in individual animals. Colitis induction resulted in
increased expression of TLR2 and TLR4 in epithelial cells
(Figure 8A, B, C and D). PRNP expression was increased both in
submucosal inflammatory cells and to some degree also in
Figure 8. In situ hybridization (ISH) of significantly regulated genes in TNBS colitis mucosal biopsies. (A and C) The expression of TLR2
and TLR4 is scattered in the epithelium and submucosal immune cells at T0. (B and D) Increased TLR2 and TLR4 expression was noted in the
epithelium at T7. (E) PRNP expression in submucosal immune cells at T0. (F) Intense PRNP expressing cells were evident in the submucosa at T12 and
also to some degree in the epithelium. (G) Intense clusters of PPARc expression in epithelial cells at T0. (H) At T12, the expression is almost abolished.
Objective x40 in all pictures.
doi:10.1371/journal.pone.0054543.g008
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epithelial cells (Figure 8F), while a substantial down-regulation of
PPARc was evident in the epithelium after induction of colitis
(Figure 8H). The in situ results correlated well with the differential
expression noted in the microarray, IL-1a (FC at T3= 8.6,
p=0.008), IL-1b (FC at T7= 4.7, p=0.047), TLR2 (FC at
T3= 5.03, p=0.005), TLR4 (FC at T3= 2.09, p,0.001), PPARc
(FC at T12=24.6, p,0.001), and PRNP (FC at T3= 2.1,
p=0.005). P-values and FCs for the target genes at every time
point are provided in Table 1.
PCR validation of selected genes
PCR was performed for the following genes: SPINK4, ADA,
and FABP1. Mean FCs for SPINK4 were 93.26 for T3 vs. T0,
4.02 for T7 vs. T0 and 1.76 for T12 vs. T0. The corresponding
FCs for ADA were 11.93, 16.87 and 13.20 and for FABP1
2199.96, 2105.60 and 2170.62 which were in accordance with
the microarray results (Figure 9).
Discussion
TNBS-colitis is widely used as a model for IBD. However, its
resemblance to human disease has not been thoroughly explored.
TNBS-colitis in rats was originally described as a model for
induction of long lasting inflammation and ulceration of the rat colon [12],
and the reproducibility was emphasized. The reproducibility and
duration/chronicity of inflammation has, however, been subject to
debate [14,41]. In the current study, we standardized the protocol
for induction of moderate TNBS-colitis in Sprague Dawley rats
and evaluated temporal changes in gene expression profiles and
biological pathways after the induction of colitis. Importantly, we
quantitatively assessed concordance of the TNBS-colitis and IBD
transcriptomes.
Doses and concentrations of TNBS used in previous studies
differ markedly and no standardized protocol has been generally
developed [14,17–20]. We therefore aimed to optimize the
method to achieve a reproducible moderate colitis. High
concentrations of TNBS (60 mg/ml), administered in small
volumes (0.29 and 0.38 ml) induced a localized severe inflamma-
tion resulting in deep colonic ulcerations, coprostasis, stenoses and
ileus. Milder inflammation and more wide spread inflammation
was achieved with lower TNBS concentrations in a larger total
volume. A TNBS concentration of 30 mg/ml in a total volume of
0.6 ml resulted in a moderate inflammation involving most of the
left colon. However, despite the use of a standardized protocol, a
slight inter-individual dissimilarity in the extension and degree of
inflammation was seen, reflected by variation in MEICS-score and
expression of the pro-inflammatory cytokines IL-1a and IL-1b.
Natural inter-individual variation and factors like anal leakage of
TNBS and incomplete bowel emptying prior to the instillation are
likely contributors to these observations. To minimize these effects,
fecal pellets in the rectum should be eliminated prior to TNBS-
instillation.
TNBS induces a hapten-mediated toxic inflammation, and
consequently has unavoidable differences compared to IBD [42].
In addition to chemical inflammation, the intestinal microbiota is
important in the development of TNBS-colitis [43]. Granulomas
have been described in approximately 50% of rats with TNBS-
colitis [12]. However, no granulomas were seen in the current
study. This may reflect disparities in the microbiota seen in
different animal housing facilities.
Endoscopic monitoring of TNBS-colitis with visual assessment
has been described. However, in those studies no biopsies were
obtained [44,45]. In another study, transcriptomic analysis of
TNBS-colitis was performed using whole colon specimens from
animals sacrificed at different time points [21]. Consequently,
temporal changes in gene expression in individual rats during
colitis development has not been investigated. Furthermore, a
comparison with a human IBD transcriptome has not been
conducted. Our approach thus allows investigators to follow the
development of colitis in individual animals visually, and collect
biopsies for histologic evaluation and genetic analyses. Endoscopy
three days after TNBS instillation allowed for a baseline evaluation
of the inflammation. Rats with comparable colitis could therefore
be identified prior to study inclusion. A similar approach has been
described using MRI to grade the inflammation [14]. In addition,
as the animals serve as their own controls it reduces the overall
study number.
Computational analysis of longitudinal gene expression profiles
in the TNBS-colitis model in this study revealed alterations such as
a down-regulation of metabolism and up-regulation of tissue
remodeling genes. This suggests that mucosal cells may be
deprived of adequate energy sources as well as exposed to pro-
fibrotic signaling cascades during the inflammatory response.
Similar changes have been reported in IBD patients [46,47] and
models of experimental colitis [21]. Additionally, we noted down-
regulation of processes including DNA replication and cell cycle,
which involved genes such as caspase 1 and 3 (Casp1/3). Casp1 is
an enzyme that proteolytically cleaves precursor forms of the
inflammatory cytokines IL-1b and IL-18, while Casp3 proteolyt-
ically inactivates IL-33, which is a member of the IL-1 superfamily
[48]. Interestingly, Casp2/2 mice are more susceptible to
inflammation-induced tumorigenesis in the colon [49], while IL-
33 was recently found to be increased in ulcerative colitis [50,51].
Additionally, previous experimental models have demonstrated
that Casp2/2 mice are also more susceptible to infections [52] and
are more sensitive to DSS-colitis [53]. Taken together, the
temporal analysis of TNBS-colitis gene expression profiles revealed
biologically relevant changes in key IBD pathways, suggesting that
the transcriptome dataset in this study is a useful resource for
further biological discovery in this animal model.
Contributions of model organisms to our understanding of
generalizable fundamental processes are irrefutable. However,
little work has been done to quantitatively assess the concordance
between TNBS-colitis and IBD transcriptomes. In our analyses,
we noted a divergence between rat and human transcriptomes at
the level of single gene loci with only 233–765 (3.8–12.5%)
concordant gene loci out of 6142 analyzed. However, several key
IBD genes were similarly regulated in the TNBS model and IBD.
Genes involved in fibrogenesis and stricture formation [54,55],
including collagen type I alpha (COL1A1), matrix metallopepti-
dase 3 (MMP3) and TIMP metallopeptidase inhibitor 1 and 2
Table 1. P-values and FCs for the target genes at every time
point.
Gene T3 T7 T12
FC P-value FC P-value FC P-value
IL-1a 8.63 0.008 3.38 0.091 1.58 0.209
IL-1b 6.16 0.063 4.74 0.047 1.94 0.071
TLR2 5.03 0.005 3.46 0.029 1.75 0.027
TLR4 2.09 ,0.001 1.36 0.001 1.67 0.005
PRNP 2.13 0.005 2.11 0.005 1.89 0.016
PPARc 24.14 ,0.001 23.05 ,0.001 24.63 ,0.001
doi:10.1371/journal.pone.0054543.t001
Correlation between TNBS-Colitis and IBD
PLOS ONE | www.plosone.org 10 January 2013 | Volume 8 | Issue 1 | e54543
(TIMP1 and TIMP2) are examples thereof. These findings are
consistent with other comparative assessments of human disease
and animal models [56,57]. Our group has shown that the REG
family proteins and CXCL10 are up-regulated in IBD [58,59].
The REG proteins probably play a role in induction of cellular
proliferation and induction of apoptosis, thus being of importance
for tissue repair and growth. CXCL10 seems to be released from
epithelial cells acting as a ligand on CXCLR3+ T-lymphocytes,
Figure 9. Graph displaying confirmatory PCR. Graph displaying FC for T3 vs. T0, T7 vs. T0 and T12 vs. T0 for SPINK4, ADA and FABP1 for both
microarray (MA) and confirmatory PCR. FC is log2 transformed for illustrative purposes. All p-values are highly significant.
doi:10.1371/journal.pone.0054543.g009
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contributing to the inflammatory response in IBD. In contrast to
these results, both REGIV and CXCL10 were down-regulated in
the TNBS-model. It is possible that the duration of the TNBS-
study was too short to detect a delayed activation of REGIV,
however the discrepancy might also reflect the difference between
IBD and TNBS-colitis. The discrepancy in regulation of CXCL10
also demonstrates the dissimilarity between human disease and
TNBS-colitis. Other chemokines like CXCL1 and CXCL2, have
previously been found up-regulated in TNBS-colitis [21] and were
up-regulated in our data. We also found CXCL16 to be 1.5 fold
elevated at T3. CXCL16 has a role in phagocytosis, mucosal
defense and Th1-mediated inflammation, and has been implicated
in the pathogenesis of IBD [60–62].
Despite differences at the level of single gene loci, considerably
higher homology was noted between TNBS-colitis and IBD at the
level of biological pathways. For KEGG-pathways 114–134 (58.5–
68.7%) of 195 pathways, while for the Reactome 515–631 (56.3–
69.0%) of 915 pathways were concordant. This result was
expected, since previous work demonstrates that pathway level
analysis is able to uncover subtle biological variability, which may
not be captured by gene expression alone [63]. Concordant
pathways included Cell junction organization, Interleukin-1 processing,
and Dysregulation of fatty acid metabolism. These pathways represent
key elements of IBD pathogenesis. For example, the ability to
organize tight junctions, adherent junctions and desmosomes are
important protective mechanisms that prevent microorganism
invasion, mucosal damage and inflammation [64]. Similarly,
aberrant regulation of IL-1a and IL-1b is a contributing
mechanism in persistent inflammation in IBD [65,66], while
alterations in the expression of genes involved in fatty acid
metabolism may contribute to the pathophysiology of ulcerative
colitis [46].
Among non-concordant pathways, we identified TRAIL signaling
as being different between the rat model and IBD. This signaling
pathway mediates apoptosis and might be of importance for T-cell
death as a therapeutic target in IBD [67].
Overall, these concordance analyses suggests that TNBS-colitis
is an appropriate IBD model for the study of specific biological
processes such as Cell junction organization and Fatty acid metabolism,
while caution needs to be exercised when analysis is based on a
single gene locus.
Other chemically induced colitis models exist. Colitis induced
through addition of the polysaccharide dextran sodium sulfate
(DSS) in the drinking water or rectal instillation of oxazolone are
examples thereof [68]. DSS and TNBS have clinical similarities
including bloody diarrhea and weight loss. However, inflamma-
tion in DDS seems to be caused by hyperosmotic damage and is
confined to the mucosa and lamina propria, in contrast to the
TNBS-model where inflammation is hapten-mediated and trans-
mural [69]. Additionally germ free mice develop a lethal colitis
when exposed to DSS [70], while a sterile colon seems to be
protective against TNBS-colitis [43]. A comparison of genetic
expression between DSS, TNBS and CD45RB transfer colitis
mice showed that DSS and TNBS had 6 and 18 concordantly up-
and down-regulated genes [71]. Another study found 152 and 22
concordantly up- and down-regulated genes between mice with
DSS-colitis and UC from a total of 1609 differentially expressed
genes [72]. In an analysis of cytokine patterns, closer resemblance
was indicated between DSS-colitis and UC, while TNBS-colitis
seemed closer to CD [73]. Oxazolone is another example of a
rectally administered substance that causes a hapten-mediated
colitis in the distal part of the colon with clinically similar
symptoms as TNBS-colitis [68,74]. Oxazolon-induced colitis is
mainly driven by Th2 cytokines, while TNBS-colitis is Th1- and
Th17-mediated [11,73,74].
Several gene knockout models in mice have been used to study
possible pathogenetic mechanisms in IBD. Deletion of the
regulatory sequence consisting of adenosine-uracil multimers
(AU-rich elements [ARE]) in the 39-untranslated region of
cytokine encoding transcripts in mice (TNF-DARE/+), results in
mice with increased transcription of TNF-a; after lipopolysaccha-
ride (LPS)-stimulation these mice develop terminal ileitis and
inflammatory arthritis [68,75]. IL-10 knockout mice develop
inflammation, mainly localized to the colon [76]. The IL-10
knockout model has highlighted the importance of IL-10 as an
anti-inflammatory cytokine. IL-10 is increased in the serum of
recovering IBD-patients [77]. IL-10 was not significantly regulated
in our TNBS-model which might suggest that IL-10 does not
participate in the healing of TNBS colitis.
We sought to validate key changes in the TNBS-colitis
transcriptome using ISH. Genes with known roles and of potential
importance in IBD were evaluated, namely IL-1a, IL-1b, TLR2,
TLR4, PPARc and PRNP. Gene expression profiling revealed
that IL-1a and IL-1b were significantly up-regulated at T3 and
T7, compared to T0, while TLR2, TLR4 and PRNP were
significantly up-regulated at every time point (T3, T7 and T12)
compared to T0. PPARc was significantly down-regulated at every
time point.
ISH confirmed that both IL-1a and IL-1b were weakly
expressed in colonic epithelial cells while high expression was
found in leukocytes and inflammatory infiltrates. Mediation of
inflammation by IL-1a and IL-1b is balanced or counteracted via
the IL-1 receptor antagonist (IL-1ra), which was significantly up-
regulated at every time point. It has previously been shown in
experimental colitis that neutralization of IL-1ra leads to more
severe inflammation [78]. In concordance with the TNBS-colitis
model, both IL-1a and IL-1b are elevated in IBD. An imbalance
between these IL-1s and IL-1ra might contribute to the
pathogenesis in IBD [65,79].
The increased TLR2 and TLR4 expression seen in the
transcriptome analysis was confirmed by ISH with dense staining
in epithelial cells at the luminal surface and in the crypt
epithelium. Hitherto, 10 TLRs have been described in humans
[6]. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR9 all recognize
bacterial products or bacterial components [80]. While TLR2 and
TLR4 were up-regulated, TLR5 was significantly down-regulated
in our TNBS-colitis model. Intestinal homeostasis between
tolerance to intestinal microflora and activation of an inflamma-
tory response appears to be dependent on the type of TLR
involved and whether basolateral or apical TLRs are activated
[81]. Similar to the TNBS-colitis model, activation of both TLR2
and TLR4 is seen in IBD [5,82,83]. Probiotic treatment also
activates TLR2, TLR4 and TLR9 and modulates cytokine
production and secretion [84]. Interestingly, IL-10 and TLR4
double knockout mice have an accelerated colitis development
compared to IL-10 and TLR9 double knockout and IL-10 single
knockout which do not develop colitis [85]. TLR2 and TLR4 up-
regulation in epithelial cells in this TNBS-colitis model as well as
the cytokine up-regulation indicate bacterial activation of mucosal
defense and inflammation [5]. Clearly, the mechanisms of TLR-
response are complicated. The mechanisms for the balance of an
adequate immune response and adaption of the innate immune
system, on one hand, and an inadequate immune response, on the
other hand, can partly be explained by tolerance development and
polarization differences in TLR-receptor distribution [86,87].
PRNP (PrPc) mRNA was significantly up-regulated in TNBS-
colitis. This was verified by ISH which showed expression in
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submucosal immune cells and some expression in epithelial cells in
animals not yet exposed to TNBS, but expression was more
pronounced after colitis induction both in the submucosal immune
cells and within the epithelium. PrPc is expressed in several tissues,
including neural tissue, gut-associated lymphoid tissue, enteroen-
docrine cells and enterocytes [28,88]. Its function is not well
known. Expression of PrPc in the host is thought to be necessary
for the propagation and transmission of prion infection [28]. In
addition, both pro- and anti-inflammatory roles have been
suggested. Reduced inflammatory infiltration has been seen in
PrPc-deficient mice upon stimulation with TLR2 and TLR4
ligands [26]. In contrast, PrPc over-expressing mice are resistant to
colitis induction with DSS while PrPc deficient mice had
significantly higher levels of inflammatory cytokines compared to
DSS-treated wild type mice [29]. Increased intestinal barrier
permeability has been demonstrated in PrPc-deficient mice,
further supporting a protecting role for PrPc [89] in colitis and
IBD.
PPARc is one of three identified isoforms of peroxisome
proliferator-activated receptors (PPARs) and is expressed in several
tissues; expression is high in the colonic epithelial cells [90,91]. It is
thought to have an important role in modulation of inflammation.
PPARc suppresses inflammatory cytokines like TNFa, interleukin-
6 (IL-6) and IL-1b [24] and maintains defensin production [25].
Gene expression analysis revealed down-regulation of PPARc
after colitis induction. In endoscopic biopsies evaluated by ISH, a
high basal expression of PPARc in non-inflamed colonic
epithelium, while a considerable down-regulation in inflamed
colon epithelium was identified. This was accompanied by down-
regulation of FABP1. FABP1 transcription, in the microarray was
confirmed by PCR. The intracellular level of FABP1 positively
regulates PPARc and the two proteins also have a direct protein-
protein interaction [92]. Regulation of FABPs is seen in IBD [46],
PPARc is down-regulated in UC [93] and gene polymorphisms of
PPARc have been implicated in the pathogenesis of CD [42,94].
PPARc-agonists have been shown to ameliorate TNBS-induced
colitis [95,96] and the PPARc ligand rosiglitazone has shown
efficacy in mild to moderately active IBD [97]. PPARc might also
inhibit tumor growth in colorectal cancer [98]. Alternatively,
FABP1 has been suggested as a biomarker of CD because a 10-
fold up-regulation was found in one study [99]. Our findings, in
contrast, are consistent with loss of PPARc-mediated anti-
inflammatory effects. This supports a potentially important
function for PPARc in the regulation of colonic inflammation
and indicates that FABPs could also be a possible target for
therapy.
Among the 20 genes with highest FC at all time points were
SPINK4; lipopolysaccharide binding protein (LBP), ADA and
RETNLB. PCR validation was performed for SPINK4 and ADA.
SPINK4 has recently been identified as a risk locus for UC [100]
and increased expression is seen in untreated celiac disease [101].
LBP transfers LPS to the LPS-signaling receptor complex (which
also contains TLR4), promotes innate immunity against gram
negative bacteria, and may serve as a marker of disease activity in
CD [102]. ADA deactivates adenosine and thus diminishes the
potentially protective effects of adenosine in mucosal inflammation
and hypoxia. A beneficial effect after inhibition of ADA has been
demonstrated in experimental colitis [103,104]. RETNLB had a
FC of 470 and 253 at T7 and T12, respectively. RETNLB-
deficiency in mice increases intestinal permeability and RETNLB
seems important to maintain intestinal homeostasis [105].
In conclusion, endoscopy with biopsies in TNBS-colitis models
is useful to visually follow temporal changes of inflammation and
obtain tissue for histologic and gene expression measurements.
TLR and interleukin activation, PPARc-inhibition and regulation
of PRNP (PrPc), occurs in both TNBS-colitis and IBD. TNBS-
colitis is an appropriate IBD-model to study specific biological
processes like TNF signaling, Cell junction organization, and Interleukin-1
processing. We conclude that the TNBS-model may be suitable for
studying agents targeting these pathways and provide translational
information for clinical studies.
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